Virios Therapeutics Announces Second Quarter 2024 Financial Results [Yahoo! Finance]
Virios Therapeutics, Inc. (VIRI)
Company Research
Source: Yahoo! Finance
- Top-line results from the Bateman Horne Center's Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the second quarter ended June 30, 2024. Key Highlights Completion of enrollment in the BHC-202 3-arm study, which is comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC. BHC-202 is being conducted by the Bateman Horne Center under an unrestricted investigational grant provided by the Company. Top line results are expected in October 2024. Ongoing blinded safety analysis of the BHC-202 study indicates that study drug (either t
Show less
Read more
Impact Snapshot
Event Time:
VIRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIRI alerts
High impacting Virios Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VIRI
News
- Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target lowered by analysts at HC Wainwright from $0.40 to $0.20. They now have a "neutral" rating on the stock.MarketBeat
- Virios Therapeutics Announces Second Quarter 2024 Financial ResultsGlobeNewswire
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024GlobeNewswire
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center [Yahoo! Finance]Yahoo! Finance
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterGlobeNewswire
VIRI
Earnings
- 8/8/24 - Beat
VIRI
Sec Filings
- 8/9/24 - Form 10-Q
- 8/8/24 - Form 8-K
- VIRI's page on the SEC website